At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 400 enrolled
Drug / intervention
TAK-850 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-Blind Parallel-Group Comparative Phase 2 Study to Evaluate the Immunogenicity and Safety of a Single Subcutaneous Injection of TAK-850 in Comparison With Influenza HA Vaccine in Healthy Adult Subjects
In Brief
A Phase 2 clinical trial evaluating TAK-850 and Influenza HA vaccine for Influenza Infection. Completed, enrolled 400 participants.
Detailed Summary
The purpose of this study is to evaluate the immunogenicity and safety of TAK-850 administered subcutaneously as a single dose versus influenza HA vaccination in an exploratory manner.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza Infection
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedSep 2015
Primary CompletionDec 2015
TodayJul 2026
First PostedSep 21, 2015
Enrollment StartSep 1, 2015
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.8 years ago
Interventions
TAK-850biological
TAK-850 subcutaneous injection
Influenza HA vaccinebiological
Influenza HA vaccine subcutaneous injection